Key result
Reduced doses of enoxaparin showed no significant difference in the composite outcome of bleeding or VTE compared to the standard dose in hospitalized underweight adults.
Why the study?
Although anti-Xa levels are inversely related to body weight, limited studies have evaluated clinical outcomes of enoxaparin dose reduction for VTE prophylaxis in underweight patients.
Does a reduced dose of enoxaparin prevent VTE without increasing bleeding risk in hospitalized underweight adult patients compared to the standard dose?
Cohort (n=1,130)
Yes
Does a reduced dose of enoxaparin prevent VTE without increasing bleeding risk in hospitalized underweight adult patients compared to the standard dose?
Answers are grounded in this paper and cite their sources.
In hospitalized underweight adults, reducing the prophylactic dose of enoxaparin did not significantly alter the incidence of bleeding or VTE compared to the standard 40 mg daily dose, though the study was limited by very low event rates.
BACKGROUND: Enoxaparin is commonly used for venous thromboembolism (VTE) prophylaxis in adult hospitalized patients. Although anti-Xa levels are inversely related to body weight, limited studies evaluated clinical outcomes of dose reduction in the underweight population. OBJECTIVE: To compare the incidence of bleeding and VTE in underweight patients receiving reduced doses of enoxaparin (< 40 mg daily) versus the standard dose (40 mg daily) for VTE prophylaxis. METHODS: who received prophylactic enoxaparin for at least 48 h. The outcomes were bleeding, VTE, and composite unfavourable outcome (bleeding or VTE). Inverse-probability-of-treatment weighting (IPTW) was used to adjust for confounding. RESULTS: We identified 1,130 eligible patients, of whom 124 patients (11%) received the reduced dose, and 1,006 patients (89%) received the standard dose. Bleeding occurred in one patient (0.8%) of the reduced dose group compared to 15 patients (1.5%) in the standard dose group (p > 0.99), VTE occurred in two patients (1.6%) in the reduced dose group compared to four patients (0.4%) in the standard dose group (p = 0.13). In the IPTW analysis, there was no significant difference in overall bleeding (odds ratio (OR) 1.4, 95% CI 0.18-10.75, p = 0.74), VTE (OR 0.3, 95% CI 0.05-1.81, p = 0.19), or the composite unfavourable outcome (OR 0.74, 95% CI 0.2-2.75, p = 0.66). CONCLUSION: There is no significant difference in the incidence of bleeding or VTE between the reduced dose and the standard dose of enoxaparin for VTE prophylaxis in underweight adult patients. Due to the low event rates in both groups, larger studies are required to delineate any differences between the two dosing strategies.
No takes yet. Share an insight, caveat, or question.
Safrah et al. (2025) conducted a cohort in Venous thromboembolism (VTE) risk in hospitalized underweight patients (n=1,130). Reduced dose enoxaparin (< 40 mg daily) vs. Standard dose enoxaparin (40 mg daily) was evaluated on Composite unfavourable outcome (bleeding or VTE) (OR 0.74, 95% CI 0.2-2.75, p=0.66). Reduced doses of enoxaparin showed no significant difference in the composite outcome of bleeding or VTE compared to the standard dose in hospitalized underweight adults.
Synapse has enriched 10 related papers. Consider them for comparative context: